There are currently no events to display.
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. Adverum has a robust pipeline that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (A1AT) deficiency and hereditary angioedema (HAE) as well as wet age-related macular degeneration (wAMD). Leveraging a next-generation adeno-associated virus (AAV)-based directed evolution platform, Adverum generates product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum has collaboration agreements with Regeneron Pharmaceuticals to research, develop, and commercialize gene therapy products for ophthalmic diseases and Editas Medicine to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. Adverum’s core capabilities include clinical development and in-house manufacturing expertise, specifically in process development and assay development.
Adverum Biotechnologies NASDAQ:
02/24/18 10:45 AM EST
Data provided by Nasdaq.
Minimum 15 minutes delayed.
- Feb 12 2018
Summary ToggleAdverum Biotechnologies Announces Closing of $69 Million Public Offering
- Feb 8 2018
Summary ToggleAdverum Biotechnologies Announces Pricing of $60 Million Public Offering of Common Stock
- Feb 7 2018
Summary ToggleAdverum Biotechnologies Announces Proposed Public Offering of Common Stock
- Jan 25 2018
Summary ToggleAdverum Biotechnologies and Editas Medicine Extend Research Collaboration
|Summary Toggle Mar 5, 2018 at 9:15 AM EST||
|Summary Toggle Mar 12, 2018 at 1:30 PM EDT||